Posted by Michael Wonder on 20 Jul 2018
NICE backs radionuclide therapy for some neuroendocrine tumours
20 July 2018 - A price cut has secured NHS funding for Advanced Accelerator Applications’ Lutathera as a treatment for some neuroendocrine tumours.
Overturning an earlier rejection, the National Institute for Health and Care Excellence has now published draft guidelines recommending the therapy for treating NETs of gastrointestinal and pancreatic origin.
Additional evidence submitted by the company for pancreatic and gastro-intestinal neuroendocrine tumours and a reduction in price helped bring the treatment’s cost-effectiveness estimates into the range considered acceptable for NHS use.-
